

LC/MS/MS ANALYSIS OF URINARY BENZODIAZEPINES AND Z-DRUGS VIA A SIMPLIFIED, MIXED-MODE SAMPLE PREPARATION STRATEGY

Jonathan P. Danaceau and Erin E. Chambers
Waters Corporation Milford, MA, USA

INTRODUCTION

Benzodiazepines are commonly prescribed drugs used for their sedative, anxiolytic, and hypnotic properties.¹ Nationally, overdose deaths from benzodiazepines have risen 600% from under 1,600/year in 2001 to 8,000 in 2014, greater than any other drug class with the exception of heroin.² So-called “Z-drugs” (zolpidem and zopiclone) are commonly used sleep aids that act in a similar manner to benzodiazepines.¹ While the use of LC/MS/MS for benzodiazepine analysis has increased in recent years, many published techniques still rely on labor intensive liquid-liquid extraction techniques.³⁻⁵

The objective of this study was to develop a simplified sample preparation and LC/MS/MS analysis strategy for these compounds. Strong cation exchange micro elution plates were used to rapidly extract these compounds from urine samples. All sample preparation steps, including enzymatic hydrolysis, were performed within the wells of the μ Elution plates, and the extraction method is simplified by eliminating conditioning and equilibration steps.

This method analyzes 18 benzodiazepine drugs and metabolites, along with zolpidem, zopiclone and N-desmethyl zopiclone.

METHODS


Extraction Procedure

200 μ L of urine was added to individual wells of a Waters Oasis® MCX μ Elution SPE plate, along with internal standards, hydrolysis buffer and β -glucuronidase enzyme. 20 deuterated internal standards were used for quantification. Samples were incubated for 1 hr. at 50 °C. After incubation, samples were quenched with 200 μ L of 4% H_3PO_4 and directly loaded onto the sorbent bed by vacuum. All samples were subsequently washed with 200 μ L of 0.02 N HCl, and 200 μ L of 20% MeOH. Samples were eluted with 2 x 25 μ L of 60:40 ACN:MeOH containing 5% strong ammonia solution and then diluted with 100 μ L of sample diluent (2% ACN:1% formic acid in water).

5 μ L of each sample was injected and analyzed by UPLC/MS/MS using a Waters’ Cortecs C18+ column (1.6 μ m; 2.1 x 100) and a Xevo® TQ-S micro mass spectrometer.

Calibrators were prepared in blank urine at concentrations ranging from 0.5-500 ng/mL. Quality control samples were prepared at 4 concentrations than covered the calibration range.

Figure 1. Extraction procedure for benzodiazepines and Z-drugs



LC Conditions

| | |
|----------------|---|
| LC System | ACQUITY I-Class (FL) |
| Column | Waters CORTECS C18+ Column, 1.6 μ m, 2.1 x 100 mm |
| Column Temp | 30 °C |
| Sample Temp | 10 °C |
| Injection Vol. | 5 μ L |
| Flow Rate | 0.5 mL/min |
| Mobile Phase A | 0.01% formic acid in water |
| Mobile Phase B | 0.01% formic acid in ACN |

Table 1. Mobile phase gradient

| Time (min) | Flow (mL/min) | % MPA | % MPB |
|------------|---------------|-------|-------|
| initial | 0.5 | 90 | 10 |
| 5.00 | 0.5 | 50 | 50 |
| 5.25 | 0.5 | 5 | 95 |
| 6.00 | 0.5 | 5 | 95 |
| 6.10 | 0.5 | 90 | 10 |
| 7.50 | 0.5 | 90 | 10 |

MS Conditions

| | |
|-------------------|------------------------------------|
| MS System | Waters Xevo® TQ-S micro |
| Ionization Mode | ESI Positive |
| Capillary Voltage | 0.5 kV |
| Desolvation Temp | 500 °C |
| Desolvation Flow | 150 L/hr |
| Source Temp | 150 °C |
| MRM Conditions | Optimized for individual compounds |

MS Conditions and Retention Times

Waters Xevo® TQ-S micro

| | Compound | RT | M+H ⁺ | MRM Product Ions | Cone Volt-age | Colli-sion Energy |
|----|-------------------------|------|------------------|------------------|---------------|-------------------|
| 1 | N-desmethyl Zopiclone | 1.06 | 375.1 | 245.0 | 6 | 14 |
| 2 | Zopiclone | 1.12 | 389.1 | 245.0 | 8 | 12 |
| 3 | Zolpidem | 1.61 | 308.1 | 235.1 | 34 | 32 |
| 4 | 7-amino-clonazepam | 1.91 | 286.1 | 121.0 | 50 | 26 |
| 5 | Flurazepam | 2.31 | 388.2 | 315.1 | 40 | 26 |
| 6 | 7-amino-flunitrazepam | 2.35 | 284.1 | 135.0 | 34 | 26 |
| 7 | Chlordiazepoxide | 2.34 | 300.0 | 227.0 | 34 | 20 |
| 8 | Midazolam | 2.53 | 326.0 | 291.0 | 16 | 36 |
| 9 | α -OH-midazolam | 2.90 | 342.0 | 203.0 | 2 | 24 |
| 10 | α -OH-triazolam | 3.76 | 359.0 | 176.0 | 28 | 24 |
| 11 | α -OH-alprazolam | 3.77 | 325.1 | 297.1 | 50 | 25 |
| 12 | Oxazepam ¹ | 3.84 | 289.0 | 103.9 | 50 | 30 |
| 13 | Nitrazepam | 3.86 | 282.1 | 180.1 | 50 | 36 |
| 14 | Lorazepam | 4.00 | 321.0 | 277.0 | 50 | 20 |
| 15 | Clonazepam | 4.09 | 316.0 | 214.1 | 54 | 42 |
| 16 | Alprazolam | 4.35 | 309.1 | 205.0 | 50 | 40 |
| 17 | Nordiazepam | 4.36 | 271.0 | 140.0 | 50 | 30 |
| 18 | Flunitrazepam | 4.41 | 314.1 | 239.2 | 50 | 30 |
| 19 | Temazepam | 4.44 | 301.1 | 177.0 | 36 | 46 |
| 20 | Triazolam | 4.47 | 343.0 | 308.0 | 28 | 24 |
| 21 | Diazepam | 5.13 | 285.1 | 154.0 | 50 | 26 |

Table 2. Individual MS conditions and retention times

RESULTS

Chromatography




Figure 2. Chromatography of benzodiazepines and Z-drugs from an extracted calibration standard. Conditions are detailed in Materials and Methods. Retention times are listed in Table 2.

Separation of critical pairs




Figure 3. Selected chromatograms from the Cortecs C18+ column. **A.** Clonazepam-d4 does not interfere with lorazepam, even at the lowest calibrator. **B.** Flunitrazepam, even at 500 ng/mL does not interfere with alprazolam-d5.

Extraction Recovery




Figure 4. Extraction recovery of benzodiazepines and Z-drugs using Oasis MCX μ Elution plates. $N = 4$ separate extractions

References

1. Jufer-Phipps, R., B. Levine: *Benzodiazepines*. In: *Principles of Forensic Toxicology*, B. Levine (Eds). AACC Press, Washington, D.C. 237-270 (2013).
2. Karithanom, M. Number of Deaths from Prescription Drugs, National Institute of Drug Abuse, National Overdose Deaths, CDC Wonder, (2015).
3. Laloup, M. et al. *Journal of Analytical Toxicology* 29(7), 616-626 (2005).
4. Marin, S.J. et al. *Journal of Analytical Toxicology* 32(7), 491-498 (2008).
5. Marin, S.J. et al. *Journal of Analytical Toxicology* 36(7), 472-476 (2012).

Representative Calibration Curves




Figure 5. Calibration curves ranged from 0.5-500 ng/mL. The minimum r^2 value was 0.997 and all mean % deviations from the curves were less than 10%.

Inter-batch Quality Control Results

| | QC 1.5 | | QC 7.5 | | QC 75 | | QC 300 | | |
|-------------------------|---------------|------|--------------|------|--------------|------|--------------|------|---------------|
| Name | Mean | %CV | Mean | %CV | Mean | %CV | Mean | %CV | Mean |
| N-desmethyl zopiclone | 99.2% | 3.8% | 96.7% | 2.4% | 96.6% | 2.9% | 97.1% | 4.7% | 97.4% |
| Zopiclone | 97.7% | 3.2% | 96.7% | 3.4% | 98.0% | 2.8% | 96.2% | 3.5% | 97.2% |
| Zolpidem | 99.4% | 3.4% | 98.8% | 1.5% | 95.8% | 1.1% | 91.7% | 1.6% | 96.4% |
| 7-aminoclonazepam | 100.4% | 1.9% | 95.6% | 1.0% | 93.8% | 2.4% | 95.1% | 2.0% | 96.2% |
| Flurazepam | 103.6% | 7.1% | 97.6% | 4.3% | 99.3% | 7.4% | 97.6% | 5.0% | 99.5% |
| 7-aminoflunitrazepam | 99.3% | 2.3% | 93.7% | 2.3% | 96.1% | 4.7% | 97.0% | 3.2% | 96.5% |
| Chlordiazepoxide | 100.5% | 1.1% | 100.3% | 2.1% | 99.3% | 1.5% | 98.4% | 3.2% | 99.6% |
| Midazolam | 103.7% | 4.4% | 104.2% | 5.4% | 102.1% | 3.1% | 98.9% | 2.0% | 102.2% |
| α -OH midazolam | 103.4% | 4.3% | 102.5% | 4.7% | 100.8% | 5.0% | 99.1% | 2.5% | 101.4% |
| α -OH triazolam | 101.5% | 8.4% | 98.8% | 4.9% | 98.3% | 4.9% | 95.1% | 2.6% | 98.4% |
| α -OH alprazolam | 104.4% | 9.6% | 101.4% | 2.2% | 99.1% | 5.9% | 97.7% | 2.4% | 100.7% |
| Oxazepam | 100.4% | 4.3% | 98.5% | 4.1% | 98.2% | 4.7% | 97.6% | 4.6% | 98.7% |
| Nitrazepam | 102.0% | 6.2% | 95.8% | 1.3% | 95.7% | 2.4% | 98.1% | 1.8% | 97.9% |
| Lorazepam | 100.3% | 6.9% | 100.2% | 4.2% | 100.8% | 5.4% | 98.7% | 4.9% | 100.0% |
| Clonazepam | 102.0% | 4.9% | 98.2% | 3.0% | 97.5% | 3.3% | 95.2% | 4.5% | 98.2% |
| Alprazolam | 107.0% | 8.7% | 94.6% | 4.7% | 95.0% | 4.6% | 98.8% | 4.5% | 98.9% |
| Nordiazepam | 106.1% | 9.0% | 106.7% | 3.7% | 101.7% | 4.6% | 95.4% | 5.2% | 102.5% |
| Flunitrazepam | 101.8% | 8.1% | 98.2% | 2.8% | 96.3% | 2.6% | 96.3% | 7.8% | 98.1% |
| Temazepam | 102.9% | 7.3% | 101.6% | 1.2% | 97.5% | 2.8% | 94.7% | 1.8% | 99.2% |
| Triazolam | 104.4% | 8.4% | 102.4% | 2.3% | 99.9% | 3.2% | 98.2% | 3.4% | 101.2% |
| Diazepam | 104.3% | 6.5% | 103.8% | 2.1% | 99.6% | 4.1% | 94.9% | 7.6% | 100.6% |
| Mean | 102.1% | | 99.3% | | 98.2% | | 96.8% | | |

Table 3. Quality control results from 4 separately extracted batches. Mean values show the average for each compound and the average for all compounds at each QC level. Individual batches had accuracies mostly within 10% of target values and % CVs under 10%

CONCLUSIONS

- Accurate, quantitative analysis of a broad panel of benzodiazepines and z-drugs
- Rapid, simplified sample preparation of urinary benzodiazapines
- Baseline separation of all critical analyte pairs
- All sample pretreatment and extraction performed in-well, eliminating transfer steps
- Concentration on the SPE device. No need for evaporation and reconstitution
- High and consistent recovery for all compounds
- Excellent accuracy and reproducibility